VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 100 patients have been enrolled in its pivotal IDE clinical trial of the Superion Interspinous Spacer (ISS).
“We are very excited about the enrollment momentum in this clinical trial”
The Superion IDE trial is a prospective, multi-center, controlled clinical trial studying the safety and efficacy of the Superion™ ISS compared to the X-STOP® in patients with moderate lumbar spinal stenosis. The national trial is being conducted at 23 leading spine surgery sites throughout the US and is expected to enroll approximately 330 patients.
"We are very excited about the enrollment momentum in this clinical trial," said Earl R. Fender, President & Chief Executive Officer of VertiFlex, Inc. "We've put a lot of emphasis into building the support and infrastructure required to execute a clinical trial of this size, and I am very pleased with the results so far. I am grateful for the effort and support from our community of investigators who have committed themselves to completing this trial. Superion offers an advanced minimally invasive solution to patients suffering from lumbar spinal stenosis. Over 1,000 patients have already received treatment globally with Superion. We have a high confidence of success in our US IDE trial, since receiving compelling clinical evidence, from independent studies in Germany and Israel, treating a total of 192 patients."